These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 8806592)

  • 1. ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies.
    Kita Y; Tseng J; Horan T; Wen J; Philo J; Chang D; Ratzkin B; Pacifici R; Brankow D; Hu S; Luo Y; Wen D; Arakawa T; Nicolson M
    Biochem Biophys Res Commun; 1996 Sep; 226(1):59-69. PubMed ID: 8806592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
    Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
    Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of cyclooxygenase-2 pathway by HER2 receptor.
    Vadlamudi R; Mandal M; Adam L; Steinbach G; Mendelsohn J; Kumar R
    Oncogene; 1999 Jan; 18(2):305-14. PubMed ID: 9927187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of erbB-2 and its ligands in growth control of malignant breast epithelium.
    Lupu R; Dickson RB; Lippman ME
    Princess Takamatsu Symp; 1991; 22():49-60. PubMed ID: 1688228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
    Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.
    Fendly BM; Winget M; Hudziak RM; Lipari MT; Napier MA; Ullrich A
    Cancer Res; 1990 Mar; 50(5):1550-8. PubMed ID: 1689212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heregulin induces tyrosine phosphorylation of HER4/p180erbB4.
    Plowman GD; Green JM; Culouscou JM; Carlton GW; Rothwell VM; Buckley S
    Nature; 1993 Dec; 366(6454):473-5. PubMed ID: 7902537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
    Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
    Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225.
    Ye D; Mendelsohn J; Fan Z
    Oncogene; 1999 Jan; 18(3):731-8. PubMed ID: 9989823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response.
    Stagg J; Sharkey J; Pommey S; Young R; Takeda K; Yagita H; Johnstone RW; Smyth MJ
    Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16254-9. PubMed ID: 18838682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ErbB kinases and NDF signaling in human prostate cancer cells.
    Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
    Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
    Bos M; Mendelsohn J; Kim YM; Albanell J; Fry DW; Baselga J
    Clin Cancer Res; 1997 Nov; 3(11):2099-106. PubMed ID: 9815602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth.
    Takai N; Jain A; Kawamata N; Popoviciu LM; Said JW; Whittaker S; Miyakawa I; Agus DB; Koeffler HP
    Cancer; 2005 Dec; 104(12):2701-8. PubMed ID: 16265675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma.
    Gilbertson RJ; Perry RH; Kelly PJ; Pearson AD; Lunec J
    Cancer Res; 1997 Aug; 57(15):3272-80. PubMed ID: 9242460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bivalence of EGF-like ligands drives the ErbB signaling network.
    Tzahar E; Pinkas-Kramarski R; Moyer JD; Klapper LN; Alroy I; Levkowitz G; Shelly M; Henis S; Eisenstein M; Ratzkin BJ; Sela M; Andrews GC; Yarden Y
    EMBO J; 1997 Aug; 16(16):4938-50. PubMed ID: 9305636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors.
    Klapper LN; Vaisman N; Hurwitz E; Pinkas-Kramarski R; Yarden Y; Sela M
    Oncogene; 1997 May; 14(17):2099-109. PubMed ID: 9160890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175.
    Schaefer G; Fitzpatrick VD; Sliwkowski MX
    Oncogene; 1997 Sep; 15(12):1385-94. PubMed ID: 9333014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of novel murine monoclonal antibodies directed against the extracellular domain of human HER2 tyrosine kinase receptor.
    Kazemi T; Tahmasebi F; Bayat AA; Mohajer N; Khoshnoodi J; Jeddi-Tehrani M; Rabbani H; Shokri F
    Hybridoma (Larchmt); 2011 Aug; 30(4):347-53. PubMed ID: 21851234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3.
    Chan SD; Antoniucci DM; Fok KS; Alajoki ML; Harkins RN; Thompson SA; Wada HG
    J Biol Chem; 1995 Sep; 270(38):22608-13. PubMed ID: 7673253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.